Home › Follicular Lymphoma › NCT06794268
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Follicular Lymphoma in the Postmarketing Setting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: • Participants must have been treated in the post-marketing setting with at least 1 infusion of lisocabtagene maraleucel (liso-cel) used for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL), including FL Grade 1, Grade 2 and Grade 3a, within the FDA-approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA Exclusion Criteria: * Participants known to be participating in investigational studies at the time of liso-cel, infusion * Participants treated with liso-cel for the treatment of R/R FL Grade 3b * Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product
About the study
The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
What is being tested
- Lisocabtagene maraleucel (biological)
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Participants: 300 · Started: Feb 4, 2025
Contact the study team
- BMS Study Connect Contact Center www.BMSStudyConnect.com · Phone: 855-907-3286
Official record on ClinicalTrials.gov — NCT06794268
Locations in the U.S.
| Wisconsin | CIBMTR, Milwaukee |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.